PINK1‐Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B‐Mediated Hippo‐YAP/TAZ Pathway
Sign Up to like & getrecommendations! Published in 2020 at "Advanced Science"
DOI: 10.1002/advs.201900860
Abstract: Abstract The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN‐induced putative kinase 1 (PINK1)‐dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined. The levels of the PINK1‐dependent mitophagy… read more here.
Keywords: multiple myeloma; pink1 dependent; dependent mitophagy; myeloma ... See more keywords
Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
Sign Up to like & getrecommendations! Published in 2025 at "Advanced science"
DOI: 10.1002/advs.202510816
Abstract: Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study,… read more here.
Keywords: multiple myeloma; type; activation; type interferon ... See more keywords
Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.24954
Abstract: Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE‐like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes of 141 patients with RRMM… read more here.
Keywords: relapsed refractory; refractory multiple; myeloma; vdt pace ... See more keywords
High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25311
Abstract: REFERENCES 1. U.S. Cancer Stat Working Group. U.S. Department of Health and Human Services. U.S. Cancer Stat Data Visualizations Tool, based on November 2017 submission data: www.cdc.gov/cancer/dataviz, June 2018. Accessed August 5, 2018. 2. Kumar… read more here.
Keywords: inpatient dose; myeloma; high inpatient; multiple myeloma ... See more keywords
Lung function impairment in pediatric patients with sickle cell anemia from Nigeria is associated with low steady state hemoglobin
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25373
Abstract: 1. NCCN. Multiple Myeloma (Version 3.2017); 2016. https://www.nccn. org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed February 15, 2017. 2. Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. J… read more here.
Keywords: relapsed refractory; refractory multiple; myeloma; multiple myeloma ... See more keywords
Antigen excess pitfall for free light chains measurements solved by ELISA assay
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25422
Abstract: 1. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221. 2. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system… read more here.
Keywords: myeloma; antigen excess; multiple myeloma; fonseca ... See more keywords
Investigation of dabigatran secretion into breast milk: Implications for oral thromboprophylaxis in post‐partum women
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25652
Abstract: REFERENCES 1. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3… read more here.
Keywords: myeloma; multiple myeloma; dabigatran secretion; secretion breast ... See more keywords
Humanized CD19‐targeted chimeric antigen receptor T (CAR‐T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26123
Abstract: Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. 9. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a metaanalysis of individual patient… read more here.
Keywords: myeloma; targeted chimeric; cd19 targeted; multiple myeloma ... See more keywords
SARS‐CoV‐2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26262
Abstract: 1. Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumabcombination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10): 1139-1149.… read more here.
Keywords: minimal residual; myeloma; multiple myeloma; residual disease ... See more keywords
Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26363
Abstract: REFERENCES 1. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501-5506. 2. Costa LJ, Brill IK, Omel J, Godby K, Kumar SK,… read more here.
Keywords: second primary; myeloma; primary malignancies; multiple myeloma ... See more keywords
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab‐containing line of therapy
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26449
Abstract: scape and its impact in multiple myeloma. Nat Commun. 2017;8(1):1893. 3. Foltz SM, Gao Q, Yoon CJ, et al. Evolution and structure of clinically relevant gene fusions in multiple myeloma. Nat Commun. 2020;11(1):2666. 4. Carrasco-Leon… read more here.
Keywords: course life; myeloma; life expectancy; clinical course ... See more keywords